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Retinoids Strongly and Selectively Correlate With
Keratin 13 and Not Keratin 19 Expression in
Cutaneous Warts of Renal Transplant Recipients
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Objective: To compare the expression of keratin (K)
13 and K19 in cutaneous warts of renal transplant re-
cipients (RTRs) and immunocompetent individuals (ICIs).
Design: Retrospective, nonrandomized immunohisto-
chemical study.
Patients and Methods: Specimens from cutaneous
warts of RTRs and ICIs were retrieved from the archives
of the Department of Pathology, University Medical Cen-
ter St Radboud, Nijmegen, the Netherlands. Twenty-
one warts from RTRs and 21 from ICIs were examined.
Nine RTRs (10 specimens) received either systemic ac-
itretin or topical all-trans retinoic acid, and their effect
on both keratins was assessed.
Main Outcome Measures: Frequency and expres-
sion patterns of K13 and K19 in warts of RTRs vs ICIs
and the effect of retinoids.
Results: A significantly higher percentage of warts of
RTRs expressed K13 compared with warts of ICIs (86%
vs 14%, 18 vs 3 cases, respectively; P.001). In warts of
RTRs, retinoid treatment correlated significantly with a
particularly strong, segmental K13 expression pattern,
which we termed zebroid. Without use of retinoids, K13
was mostly restricted to suprabasal single cells. Keratin
19 was absent in all warts of both patient groups.
Conclusions: Retinoids strongly correlate with K13 in
a characteristic zebroid pattern in warts of RTRs, mak-
ing K13 a sensitive marker for retinoid bioactivity in
skin (lesions) of RTRs. In non–retinoid-treated RTRs,
K13 is also frequently found in warts but without the
dramatic zebroid pattern noted in retinoid-treated
warts.
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E PITHELIAL KERATINS com-prise a heterogenous groupof acidic (type I) and neu-tral-to-basic (type II) pro-teins. As a general rule, they
are coexpressed in specific pairings, each
pair consisting of a type I and a type II kera-
tin (K). For instance, in normal adult skin,
keratin pairs K5/K14 and K1/K10 pre-
dominate in the basal layer and the su-
prabasal compartment, respectively.1
The type I keratins K13 and K19 are
usually expressed separately in adult epi-
thelia. Combined expression occurs only in
fetal skin. Both keratins are thought to be
absent in normal skin of adults except at cer-
tain body sites, such as the penile foreskin,
which still contains K13. Furthermore, K13
is abundantly present in adults in internal
stratified epithelia and is associated (with
terminal differentiation) with suprabasal ex-
pression.1-4 Expression of K19 in adults is
found in simple epithelia, such as most glan-
dular epithelia.
In the past few years, several murine
and in vitro studies have demonstrated that
vitamin A and its derivates (retinoids) are
important regulators of epidermal differ-
entiation and affect keratin gene expres-
sion. In cultured keratinocytes, the induc-
tion of an embryonic type of differentiation
by retinoids with reinduction of K13 and
K19 expression has been well docu-
mented.5,6 In vivo topical application of
retinoids on photo-aged human skin also
showed induction of K13.7
Althoughretinoidsareusedaschemo-
preventiveagents for inhibitingskincancer
in renal transplant recipients (RTRs),8,9 to
the best of our knowledge there are no
studies regarding the effects of retinoids on
keratin expression in the skin or skin le-
sions of these patients.
Renal transplant recipients develop
multiple warts and skin neoplasms. Immu-
nosuppressive treatment, sun exposure, and
viral infection with human papillomavirus
are all implicated in the etiology of cutane-
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ous tumorigenesis in RTRs.10-14 The frequent simulta-
neous occurrence of warts and skin cancers in RTRs led
us to the assumption that the verrucae or warts in RTRs
might be more prone to become malignant than equiva-
lent lesions inhealthy immunocompetent individuals (ICIs).
The existence of high- and low-risk papillomas was pre-
viously shown in mice models of cutaneous carcinogen-
esis.15 Interestingly, these high-risk papillomas expressed
K13, which was absent in low-risk papillomas.
The present study shows that RTR-associated warts
in contrast to warts in normal ICIs indeed show pro-
nounced K13 expression.This suggests that altered kera-
tin expression may reflect an important molecular event
inherent in the malignant degeneration of warts in RTRs.
Furthermore, this K13 expression in warts of RTRs
strongly correlates with retinoid therapy, but, in con-
trast to findings in animal studies and in cultured hu-
man keratinocytes,5 we could not demonstrate an effect
of retinoids on K19 expression in these patients. Retinoid-
related K13 expression in epithelial skin lesions of RTRs
displays a highly characteristic pattern, which we termed
zebroid, making K13 a useful marker for evaluating the
effect of retinoid treatment in these patients.
RESULTS
GENERAL ASPECTS OF IMMUNOSTAINING
FOR K13 AND K19
In all cases, immunostaining for K13 was restricted to
the cytoplasm. Slight variations in staining intensity were
observed in lesional skin comparing antibodies 1C7 and
2D7 with overall stronger staining with the 2D7 anti-
body. Principally, however, the staining pattern of le-
sional skin with both antibodies was identical. Normal
MATERIALS AND METHODS
TISSUE SAMPLES
For this retrospective immunohistochemical study, we re-
trieved formalin-fixed and paraffin-embedded skin speci-
mens from warts of RTRs (21 specimens from 18 patients;
average age, 50.8 years; mean duration of immunosuppres-
sion, 16.4 years) and healthy ICIs (21 specimens from 19
patients; average age, 33.3 years) from archival material at
the Department of Pathology, University Medical Center
St Radboud, Nijmegen, the Netherlands.
RETINOID TREATMENT
Nine RTRs (10 specimens) received retinoids. In 3 pa-
tients (4 specimens), topical all-trans retinoic acid (con-
centration, 0.025%-0.05%) was used, and 6 patients re-
ceived systemic acitretin (dose at time of biopsy, 10-35 mg).
Patients taking systemic acitretin participated in a clinical
trial, unrelated to the present study, studying the effects
of systemic retinoids on cutaneous carcinogenesis in RTRs.
Inclusion criteria for this trial were either the presence of
at least 1 squamous cell carcinoma (SCC) in the patient’s
history or the presence of 10 or more actinic keratoses, with
at least 1 confirmed histologically. Initially, most patients
taking acitretin started with 30 to 35 mg/d, a dosage that
prevented SCCs in RTRs in an earlier study.8 However, in
a relatively large number of patients, doses of acitretin had
to be lowered because of mucocutaneous adverse effects
(peeling of palms and soles and/or cheilitis). Retinoid- and
non–retinoid-treated patients showed no obvious differ-
ences with respect to duration, dosage, and type of immu-
nosuppression, all factors implied in the etiology of skin
cancers in immunosuppressed patients (data not shown).
HISTOPATHOLOGIC EXAMINATION
Histologic examination of all studied lesions was revised
according to World Health Organization definitions of ver-
rucae.16 The verrucae consisted predominantly of com-
mon warts or verrucae vulgares, with a smaller group of
verrucae plana, especially in ICIs, usually on the hands and
feet. Condyloma acuminata and anogenital warts were not
included.
IMMUNOHISTOCHEMICAL ANALYSIS
Immunohistochemical analysis was performed on all speci-
mens by using standard avidin-biotin-peroxidase com-
plex system with either diaminobenzidine and/or 3-amino-
9-ethylcarbazole as the chromogens. In brief, 4-µm-thick
paraffin sections were deparaffinized, hydrated, and washed
in buffered phosphate.
For K13 staining, sections were cooked in buffered ci-
trate (10mM, pH 6.0) in a microwave oven 2 times for 5
minutes each (600 W). After a cooling down period of (at
least) 20 minutes and preincubation with 20% normal horse
serum for 15 minutes, the sections were incubated with un-
diluted primary antibody overnight at 4°C. We used 2 mouse
monoclonal primary antibodies, 1C7 (immunoglobulin G2a)
and 2D7 (immunoglobulin G2b), both recognizing K13.17
As a positive control, normal esophageal tissue was used.
After incubation with primary antibodies, sections were in-
cubated for 30 minutes with biotinylated horse antimouse
(1:200 dilution) (Vector Laboratories, Burlingham, Calif),
followed by incubation for 45 minutes with avidin-biotin
complex (1:50 dilution) (Vector Laboratories). For devel-
opment with 3-amino-9-ethylcarbazole, avidin-biotin com-
plex concentrations were doubled.
For K19 immunohistochemical analysis, (mouse)
monoclonal antibody RCK 108 (Biogenex, San Ramon,
Calif) was used. Besides different pretreatment (0.1% pro-
nase for 10 minutes), the same procedure as used for K13
was followed. Eccrine ducts and sweat glands served as posi-
tive internal controls. Sections were counterstained with
Mayer hematoxylin for 2 minutes.
Immunoreactivity was scored as negative, slightly posi-
tive in a suprabasal single-cell pattern (10% lesional ke-
ratinocytes positive), or strongly positive in a suprabasal
segmental columns pattern (zebroid pattern). Scoring was
performed without knowledge of patient history and use
of retinoid therapy.
The Pearson 2 test was used for all statistical analy-
ses, and significance was set at P.05.
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esophagus was used as a positive control and showed
strong diffuse suprabasal staining.
Keratin 19 immunostaining was also localized in the
cytoplasm. Eccrine ducts and sweat glands, serving as in-
ternal controls, showed marked positivity.
EXPRESSION OF K13 AND K19 IN WARTS
OF RTRs VS ICIs AND EFFECTS
OF RETINOID TREATMENT
There was a significant difference in K13 expression be-
tween warts of RTRs and warts of ICIs (P.001). A high
percentage of warts of RTRs (86%, 18 cases) showed K13
expression, whereas in benign warts of ICIs almost all
lesions were negative except for 3 (14%) of 21 with su-
prabasal single-cell positivity (Table 1 and Figure 1).
This statistical difference in K13 positivity remained when
we excluded retinoid-treated patients: 82% K13 positiv-
ity in non–retinoid-treated RTRs vs 14% in controls
(P.001). Besides number of positive specimens, the pro-
portion of positive lesional cells also differed and was more
pronounced in warts of RTRs: the 3 positive warts of ICIs
showed only suprabasal single-cell positivity (Figure 2);
in RTRs, half of the 18 positive warts also showed this
suprabasal single-cell positivity, whereas the other half
showed strong positive staining in a remarkable pattern
of segmental positive suprabasal full epithelium thick-
ness columns (zebroid pattern) (Figure 1B, D and Fig-
ure 2). This particular pattern was not linked to eccrine
ducts or hair follicle structures; the latter actually seemed
to be spared. This zebroid pattern correlated with reti-
noid treatment (topical and systemic) when comparing
retinoid-treated RTRs (warts and in situ SCCs) with non–
retinoid-treated RTRs (Table 2) (P.001). Only 1 pa-
tient without (anamnestically traceable) retinoid treat-
ment exhibited the same K13 expression pattern.
Most warts were superficially excised, with no peri-
lesional skin available. In 1 retinoid-treated RTR, the
perilesional skin showed K13 positivity comparable with
the previously described zebroid pattern. All warts in both
groups were negative for K19, with use of retinoids hav-
ing no demonstrable effect on K19 expression (Figure
1C-D).
COMMENT
Data from numerous animal and in vitro studies5,6,18-20
with cultured human keratinocytes indicate that reti-
noids affect epidermal proliferation and differentiation.
Retinoids proved to repress differentiation-specific ker-
atins (K1/K10) and strikingly reinduced expression of K13
and K19, 2 keratins that are only coexpressed in fetal skin
and are not usually present in the epidermis of adults.2,4
In contrast to these findings of coupled K13 and K19 in-
duction by retinoids, Agarwal et al21 were the first to re-
port uncoupled regulation of K13 and K19 expression
in a human SCC cell line.
Our in vivo data with immunohistochemical evalu-
ation of K13 and K19 expression in warts of RTRs vs ICIs
show that retinoids used as chemoprotective agents in
Table 1. K13-Positive and K13-Negative Warts
in RTRs and ICIs*
Warts, No. (%)
RTRs
(n = 21)
ICIs
(n = 21)
K13 positive 18 (86) 3 (14)
K13 negative 3 (14) 18 (86)
*K13 indicates keratin 13; RTRs, renal transplant recipients; and ICIs,
immunocompetent individuals.
A B
C D
E F
G H
Figure 1. A, Hematoxylin-eosin staining of a wart from a retinoid-treated
renal transplant recipient (RTR) (original magnification 40).
B, Immunohistochemical analysis of a wart from a retinoid-treated RTR for
keratin (K) 13 (monoclonal antibody 2D7, with diaminobenzidine as the
chromogen) showing the particularly strong 3+ positive zebroid pattern of
alternating suprabasal columns of K13-positive and K13-negative
keratinocytes. This zebroid pattern was significantly correlated to retinoid
treatment in RTRs (original magnification 40). C and D, Wart of a
retinoid-treated RTR showing uncoupled regulation of K13 and K19
expression by retinoids, with strong zebroid pattern K13 positivity (D),
whereas K19 expression is absent (C). The arrows (C) point to K19-positive
sweat glands, which serve as an internal control (original magnification
40). E, Hematoxylin-eosin staining of a wart from an immunocompetent
individual (ICI) (original magnification 40). F, Immunohistochemical
analysis of a wart from an ICI for K13 (2D7, diaminobenzidine) showing
suprabasal single-cell positivity (arrow). This pattern of K13 expression was
also typical of warts from non–retinoid-treated RTRs (original magnification
40). G, In situ squamous cell carcinoma (ISSCC) of an RTR showing K13
(2D7) expression partially centered around hair follicle structures (original
magnification 40). This staining pattern differs considerably from the
retinoid therapy–related zebroid K13 pattern. H, Perilesional skin specimen
from an ISSCC of an RTR receiving retinoid treatment. Immunohistochemical
analysis of K13 (2D7) shows the same zebroid pattern as in lesional skin of
most warts of retinoid-treated RTRs (original magnification 25).
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RTRs for preventing skin cancer also strongly relate only
to K13, and not K19, expression. Our finding of reti-
noid therapy–related uncoupled K13 and K19 expres-
sion in these patients could be 3-fold. First, the retinoid
concentration in our patients could be sufficient to en-
hance K13 expression but not K19 expression. Earlier
findings6 in human epidermal cultures showed stronger
induction of K13 than K19 by retinoids with an already
marked increase of K13 in response to low levels of reti-
noids, whereas for K19 induction a higher retinoid con-
centration was necessary. Although the dosage of sys-
temic retinoids taken by many of our patients had to be
lowered during treatment because of severe mucocuta-
neous adverse effects, no induction of K19 was found in
patients still receiving the higher dosages of acitretin. Sec-
ond, the response of keratinocytes to retinoids in vitro
might not be representative of the response in vivo, and
retinoids in humans in vivo might not induce an embry-
onic type of differentiation and might only selectively in-
duce K13 expression. In the only previous in vivo study7
on the effects of retinoids in photo-aged skin only K13,
and not K19, expression was studied. Finally, this dif-
ferentiation toward esophageal-type epithelium in con-
trast to so-called embryonic-type differentiation found
in animals and in vitro could be specific for skin and skin
lesions in RTRs: earlier studies19 already showed that ef-
fects of retinoids differed in normal compared with dis-
eased keratinocytes.
Retinoid treatment significantly correlated with a spe-
cific pattern of K13 expression in skin lesions of RTRs.
This pattern, which we termed zebroid because of alter-
nating suprabasal columns of K13-positive and K13-
negative keratinocytes, is suggestive of a genetic mosa-
icism, reflecting clonal expansion of genetically altered
stem cells. In warts and slightly dysplastic skin of RTRs,
segments of epidermis may contain keratinocytes with a
genetic abnormality, making them more susceptible to
inductive actions of retinoids. Future studies might un-
ravel the underlying genes that are involved in this pro-
cess and whether, for instance, (transforming types of)
human papillomavirus might play a role.22
Interpretation of the biological impact of K13 ex-
pression in retinoid- and non–retinoid-treated warts of
RTRs could be 2-fold. The first interpretation relates the
presence of K13 in skin to differentiation, in parallel to
internal squamous epithelia, in which K13 is restricted to
the suprabasal epithelial compartment and is associated
with differentiation. Retinoids, by inducing K13 expres-
sion or directing keratinocytes toward (esophageal) dif-
ferentiation, might be chemopreventive by “freezing” cells
in this differentiated state and preventing them from (fur-
ther) dedifferentiating. Results of previous studies6,23,24 of
retinoid effects on epidermal keratinocytes have shown that
in response to retinoid treatment, higher molecular weight
keratins, typically encountered in squamous epithelia, dis-
appear, and synthesis of 2 new low molecular-weight ker-
atins, a 40- and a 52-kd keratin, corresponding to K19 and
K13, respectively, is enhanced. In the absence of vitamin
A, the opposite occurs, with an enhanced terminal epi-
dermal type of differentiation.25 Retinoid-induced esoph-
ageal-type differentiation could provide an explanation for
the cosmetic improvement of lesional skin in these RTRs,
who often had multiple hyperkeratoses before treatment:
esophageal epithelium is, in contrast to the keratinizing
epidermis, a nonkeratinizing squamous epithelium. By in-
ducing nonkeratinizing differentiation, retinoids could
lower the number of hyperkeratotic skin lesions. As an ad-
verse effect, in normal skin the diminished cutaneous ke-
ratinization caused by retinoids leads to desquamation of
palms and soles, which usually show the most prominent
keratinization. On the lips, the outer cutaneous side be-
comes more vulnerable because of differentiation toward
wet epithelium, leading to cheilitis, another known ad-
verse effect of acitretin treatment also present in our pa-
tients.8,9,26
The second interpretation relates the presence of K13
to a more dedifferentiated and potentially malignant phe-
notype. Regarding cutaneous carcinogenesis, malignant
transformation is heralded by a switch from production
of high-molecular-weight keratins usually present in adult
skin (K1/K10) to low-molecular-weight keratins also char-
acteristic of fetal skin and simple epithelia (eg, K8/K18
and K19).1 Presence of K13, a low-molecular-weight em-
bryonic keratin, would fit within this concept. It is tempt-
ing to attribute relevance to the high frequency of K13
in warts of RTRs and to speculate that it may be related
to the higher susceptibility of warts in these patients to
become malignant. This would be analogous to mouse
models on skin carcinogenesis in which aberrant K13 ex-
pression is a consistent finding in chemically and v-Ha-
ras–induced papillomas and SCCs.15,27,28 In in situ SCCs
of RTRs and ICIs we found frequent K13 expression in
75% and 45% of lesions, respectively (20 in situ SCCs
25
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Figure 2. Keratin 13 expression patterns in warts of renal transplant
recipients (RTRs) vs immunocompetent individuals (ICIs).
Table 2. Strong Keratin 13 (K13) Positivity (Zebroid Pattern)
and Nonzebroid K13 Positivity vs Retinoid Therapy
in Renal Transplant Recipients
Warts, No. (%)
Retinoid Treated
(n = 10)
Non−Retinoid Treated
(n = 11)
K13 zebroid pattern 9 (90) 1 (9)
K13 nonzebroid pattern 1 (10) 10 (91)
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tested within each group, data not shown), which is in
concert with this second hypothesis. The pattern of K13
expression in in situ SCCs of both groups was different
from the retinoid therapy–related K13 expression (ze-
broid pattern, compare Figure 1B, G). Only 4 RTRs with
in situ SCCs used retinoids, and in these patients the
retinoid therapy–related zebroid K13 pattern was most
pronounced or only present in perilesional, slightly dys-
plastic skin (Figure 1H).
When this latter interpretation would be applicable
to retinoid-related K13 expression, use of retinoids might
actually be dangerous for these patients. This is contra-
dicted by studies of the long-term safety of retinoid therapy,
since no increased incidence of skin cancer is reported.29
Studies of skin cancer chemoprophylaxis with retinoids
in RTRs actually showed reduction in the skin cancer
incidence.8
In conclusion, this retrospective in vivo study of em-
bryonic keratin expression in warts of RTRs shows that
retinoids strongly relate to K13 but not K19 expression.
By keeping keratinocytes in this esophageal-type differ-
entiation, retinoids might act chemopreventively. Reti-
noids correlate with a highly distinctive and strong K13
expression, which we termed zebroid, making K13 a use-
ful marker for evaluating retinoid treatment in these pa-
tients. The alternating zebroid K13 pattern is suggestive
of an underlying genetic mosaicism. Even in the ab-
sence of retinoids, a significantly higher percentage of K13
positivity is found in warts of RTRs compared with warts
of ICIs. Future prospective, randomized, and well-
controlled studies need to establish the relevance of this
finding and whether K13, in analogue to mouse models
of skin carcinogenesis, might become a predictive marker
for malignant progression.
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